Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer

February 23, 2017

Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

Findings published in the Feb. 23 online issue of Molecular Cell determined PGK1 as instrumental in regulating both cell metabolism and , a cellular process crucial to tumor development and maintenance. In previous studies, PGK1 was shown to play a role in coordinating cellular activities tied to cancer metabolism and brain tumor formation, and is associated with tumor metastasis and drug resistance.

"Our finding that PGK1 acts as both a glycolytic enzyme and a protein kinase in cell metabolism, autophagy, and cell proliferation greatly enhances our understanding of protein enzymes controlling cellular function," said Zhimin Lu, M.D., Ph.D., professor of Neuro-Oncology. "Because it regulates both autophagy and , PGK1 proves its significance in maintaining , thus offering a potential new approach for cancer treatment."

Lu's team found that PGK1 unexpectedly impacts the protein Beclin1 through phosphorylation, which modulates protein function. Beclin1 plays a central role in autophagy, a "recycling" process allowing cells to thrive even when starved of nutrients and/or oxygen. Autophagy has been increasingly linked to cancer since it permits tumors to access vital energy sources and necessary to grow and spread.

The researchers observed that lack of oxygen and the essential amino acid glutamine resulted in a complex protein-related chain of events where PGK1 phosphorylates Beclin1, which is required for autophagy and brain tumor development. The process is thought to be one reason why glioblastoma patients generally have poor prognoses.

"Upregulated tumor-protective autophagy is one of the reasons for cancer treatment resistance," said Lu. "These findings suggest that approaches inhibiting PGK1-regulated autophagy are likely to increase efficacy. Further investigations into this area of research are underway."

Explore further: PGK1 protein promotes brain tumor formation and cancer metabolism

Related Stories

PGK1 protein promotes brain tumor formation and cancer metabolism

March 3, 2016
PGK1, a glycolytic enzyme, has been found to play a role in coordinating cellular processes crucial to cancer metabolism and brain tumor formation, according to results published in today's online issue of Molecular Cell. ...

Study suggests that autophagy inhibitors could improve efficacy of chemotherapies

October 24, 2016
Chemotherapies treat cancer by killing tumor cells, but certain types of chemotherapy can also drive an immune system response to target and destroy the remaining tumor cells.

Role for autophagic cellular degradation process in maintaining genomic stability

November 29, 2016
Centrosomes play an essential role in cell division by organizing the protein framework on which chromosomes assemble and then separate prior to division into daughter cells. Centrosomes are made up of a pair of centrioles, ...

Inducing metabolic catastrophe in cancer cells

August 31, 2015
A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

Protein induces self-destruction in cancer cells

January 21, 2015
The role of a phosphatase protein in promoting the self-destruction of healthy cells and the progression of ovarian cancer has been identified by A*STAR researchers. Known to be overexpressed in cancer cells, the protein, ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.